RA drug benefits 'not different'

Anti-tumour necrosis factor (TNF) drugs have the same clinical efficacy as other DMARDs, say US and Austrian researchers.

Anti-TNF drugs in combination with methotrexate are recommended as a second-line treatment for rheumatoid arthritis (RA) if patients fail to respond to DMARDs, according to NICE.

But a systematic review of 23 head-to-head trials into RA drugs showed no major or clinically important differences between the two types of drugs when used as monotherapy.

All of the trials studied included at least 100 participants and 12 weeks' follow-up. Anti-TNF drugs studied included adalimumab, etanercept and infliximab, and DMARDs were limited to methotrexate, leflunomide and sulfasalazine.

In trials comparing monotherapy with each type of drug, anti-TNF drugs resulted in better radiographic outcomes than other DMARDs.

However, when the American College of Rheumatology (ACR) response criteria was considered there was little difference in outcomes for ACR 20, 50 or 70 response rates.

Overall, combinations of treatment were found to be more effective than monotherapy.

But there is insufficient evidence to decide which combination is best, said the researchers.

They warn that, because most of the studies considered were short term, long-term safety issues may change the benefit and harm ratios of the different types of drugs.

rachel.liddle@haymarket.com

Annals of Internal Medicine 2007 Online

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

COVID-19 death rate highest among BAME groups, delayed PHE review confirms

COVID-19 death rate highest among BAME groups, delayed PHE review confirms

Death rates from COVID-19 are highest among patients from BAME groups, according...

GPs face hundreds of complaints over shielding and PPE during pandemic

GPs face hundreds of complaints over shielding and PPE during pandemic

GP practices have faced hundreds of complaints over issues including shielding and...

More than 3,600 GP partners lost in four years as decline accelerates

More than 3,600 GP partners lost in four years as decline accelerates

The number of full-time equivalent (FTE) GP partners in England fell by 3,636 between...

COVID-19 pandemic leaves 2.4m patients stuck in cancer care backlog

COVID-19 pandemic leaves 2.4m patients stuck in cancer care backlog

Around 2.4m patients are waiting longer for cancer tests or treatment because of...

PHE report delayed on how ethnicity affects COVID-19 outcomes

PHE report delayed on how ethnicity affects COVID-19 outcomes

Public Health England (PHE) has missed its 31 May deadline for reporting on how factors...

Lockdown complacency threatens second COVID-19 spike that could 'overwhelm' NHS

Lockdown complacency threatens second COVID-19 spike that could 'overwhelm' NHS

Complacency around easing coronavirus lockdown measures could trigger a second wave...